CXCL1 and metabolic dysfunction-associated steatohepatitis: In addition, cytokine array analyses revealed that pharmacological inhibition of TLR4 receptor with TAK‐242, but not nmMLCK with ML‐7, tended to decrease the ability of NASH fEVs to increase IL‐6, IL‐8, CCL2 and CXCL1 (Figure S1).